Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Influence of Additional Treatments, Injected Activity and Mean Dose to the Tumor on the Overall Survival of Patients Undergoing Transarterial Radioembolization (TARE)

Version 1 : Received: 12 January 2024 / Approved: 13 January 2024 / Online: 15 January 2024 (10:02:56 CET)

A peer-reviewed article of this Preprint also exists.

Quartuccio, N.; Ialuna, S.; Scalisi, D.; D’Amato, F.; Barcellona, M.R.; Bavetta, M.G.; Fusco, G.; Bronte, E.; Musso, E.; Bronte, F.; Picciotto, V.; Carroccio, A.; Verderame, F.; Malizia, G.; Cistaro, A.; La Gattuta, F.; Moreci, A.M. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE). Curr. Oncol. 2024, 31, 1504-1514. Quartuccio, N.; Ialuna, S.; Scalisi, D.; D’Amato, F.; Barcellona, M.R.; Bavetta, M.G.; Fusco, G.; Bronte, E.; Musso, E.; Bronte, F.; Picciotto, V.; Carroccio, A.; Verderame, F.; Malizia, G.; Cistaro, A.; La Gattuta, F.; Moreci, A.M. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE). Curr. Oncol. 2024, 31, 1504-1514.

Abstract

We present our preliminary experience with transarterial radioembolization (TARE) with Yt-trium-90, and investigate the influence of additional treatments, injected activity, mean dose to the tumor on overall survival (OS). Our database was interrogated to retrieve patients who had undergone TARE with Yttrium-90 (90Y) glass or resin microspheres. The following information were searched: 1) type of pathology; 2) sex; 3) age; 4) administered activity; 5) mean dose to the tumor; 6) additional treatments; 7) OS. The OS of the different groups of patients were compared (p<0.05). A bivariate correlation (p<0.05) was used to investigate the association between injected activity and OS, and between mean dose to the tumor on OS. Thirty-nine patients were retrieved (Sex: 27 M, 12 F; mean age: 61.26 ± 14.95 years): 23 with hepatocellular carcinoma (HCC) and 16 with colorectal cancer (CRC) liver metastasis. Globally, patients with HCC demonstrated a sig-nificantly longer OS than those with CRC liver metastasis (22.66±19.11 vs. 10.41±8.75 months; p=0.022). Among patients with CRC liver metastasis, those receiving TARE and additional treatment demonstrated a longer OS than patients receiving only TARE (23.50±19.76 months vs. 8.54±5.31; p=0.018), there was a direct correlation between injected activity and OS (R=0.55, p=0.034) and between mean activity reaching the tumor and OS (R=0.812; p=0.008). Patients with HCC receiving TARE achieved a longer OS than those with CRC liver metastasis. Additional treatments, increasing injected activity and higher mean dose to the tumor seem beneficial for outcome, especially in patients with CRC liver metastases.

Keywords

transarterial radioembolization; hepatocellular carcinoma; liver metatastasis; microspheres

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.